BBA
CRL icon

Braun-Bostich & Associates’s Charles River Laboratories CRL Stock Holding History

Braun-Bostich & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-262
Closed -$59K – 92
2020
Q3 		$59K Buy
+262
New +$54.4K 0.06% 142

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Braun-Bostich & Associates's CRL Position: Q4 2020 in Review

Braun-Bostich & Associates sold out of Charles River Laboratories (CRL) in Q4 2020, closing a stake of 262 shares — an estimated $59K sold.

Braun-Bostich & Associates first reported a position in CRL in Q3 2020 and held it in 1 quarter. The position peaked at $59K in Q3 2020. 538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Braun-Bostich & Associates reported no remaining Charles River Laboratories position as of Q4 2020 after selling out during the quarter.
  • Braun-Bostich & Associates sold 262 Charles River Laboratories shares in Q4 2020, an estimated $59K.
  • Braun-Bostich & Associates first reported a position in Charles River Laboratories in Q3 2020 and held it in 1 quarter.
  • Braun-Bostich & Associates's Charles River Laboratories position peaked at $59K in Q3 2020.
  • 538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Braun-Bostich & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.